Jilin Province Huinan Changlong Bio-pharmacy Company Limited (HKG:8049)

Market Cap	1.13B +43.3%
Revenue (ttm)	1.02B +10.5%
Net Income	200.50M +6.6%
EPS	0.36 +6.6%
Shares Out	560.25M
PE Ratio	5.64
Forward PE	n/a
Dividend	0.27 (13.25%)
Ex-Dividend Date	Jun 24, 2025

Volume	64,000
Average Volume	82,400
Open	2.020
Previous Close	2.060
Day's Range	1.980 - 2.020
52-Week Range	1.405 - 2.550
Beta	0.33
RSI	32.59
Earnings Date	Mar 30, 2026

About HKG:8049

Jilin Province Huinan Changlong Bio-pharmacy Company Limited manufactures and distributes Chinese medicines and pharmaceutical products in the People’s Republic of China. The company provides Edaravone injection, compound brain comfort capsules, haikun kidney capsules, cefpirome sulfate for injections, Cefpiramide for injections, anti-bone hyperplasia tablets, Lysine zinc gluconate tablets, and Qianlie Guihuang Tablets. It markets its products under the Changlong and Qing Tong brands. The company also engages in the manufacture and distribution...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1989
• Employees: 798
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 8049

Financial Performance

In 2024, HKG:8049's revenue was 881.16 million, an increase of 4.71% compared to the previous year's 841.55 million. Earnings were 184.25 million, an increase of 24.32%.

Financial numbers in CNY